Advanced Low Air Loss Therapy for Pressure Injury Prevention
The Joerns DermaFloat® Low Air Loss (LAL) Mattress System is an advanced mattress designed to help prevent and treat pressure injuries while maximizing patient comfort in hospitals, long-term care facilities, rehabilitation centers, and home care settings. Combining low air loss technology with gentle pulsation therapy, the system continuously redistributes pressure, reduces heat and moisture buildup, and supports a healthy skin microclimate to help lower the risk of pressure ulcers.
Designed for patients requiring extended bed rest, the DermaFloat LAL promotes comfort, supports circulation, and provides consistent therapeutic pressure redistribution. As a full mattress replacement, it accommodates users weighing up to 500 lbs., making it a dependable solution for pressure injury prevention, wound care, and long-term patient support.
Features Designed for Superior Pressure Relief & Patient Comfort
- Advanced True Low Air Loss Therapy: True low air loss technology continuously circulates air to wick away heat and moisture, helping maintain a healthy skin microclimate, reduce skin maceration, and lower the risk of pressure injuries.
- 20-Cell Pressure Redistribution System: Twenty individually responsive air cells evenly distribute body weight to minimize pressure points, improve comfort, and provide effective pressure redistribution therapy for patients at risk of pressure ulcers.
- Antimicrobial, Fluid-Resistant Therapy Cover: The low-shear, low-friction therapy cover is treated with antibacterial and antifungal protection while remaining fluid-resistant and moisture vapor permeable to help reduce friction, protect skin integrity, and support infection control.
- Emergency Safety Support During Power Loss: A built-in 2-inch safety base remains inflated for up to 12 hours during power outages or patient transport, helping prevent bottoming out and ensuring continuous patient protection.
- Integrated CairRails® Side Air Bolsters: Inflatable side air bolsters provide added edge stability and fall protection, helping improve patient safety during repositioning, transfers, and overnight care.
- Extra-Wide 42-Inch Therapeutic Surface: The spacious 42-inch mattress width enhances patient comfort while giving caregivers additional room to perform treatments, reposition patients, and deliver daily care more efficiently.
- Three Therapeutic Treatment Modes: Choose between Autofirm, Therapy, and Pulsate modes to simplify patient transfers, optimize pressure redistribution, and enhance long-term comfort with customizable therapy.
- Rapid CPR Deflation System: The quick-release CPR valve allows for immediate mattress deflation, providing fast access to a firm surface for emergency resuscitation when every second matters.
Joerns DermaFloat Low Air Loss Mattress System Specifications
| Maximum Weight Capacity | 500 lbs. |
| Dimensions (LxWxD) | 80 x (36 or 42) x 10 in. |
| Number of Zones | 3 |
| Number of Therapy Cells | 20 Horizontal Cells |
| Depth of Therapy Cells | 8 in. |
| Lower Safety Cell Depth | 2 in. |
| CPR Quick Deflation | Yes |
| CairRails/Side Bolsters | CairRails |
| Control Unit Dimensions (WxHxD) | 7.5 x 12.25 x 5.5 in. |
| Control Unit Modes of Operation | Autofirm, Therapy and Pulsate |
| Therapy / Comfort Settings | 8 |
| Pressure Redistribution Clinical Indications | Stage 1 – 4 Pressure Injuries; Moisture Management Required; Rehabilitation; Burns; Neurology; Dermatology; Amputations |
| Pain Management Clinical Indications | AIDS; Arthritis; Oncology |
| Mattress Warranty | 2 Years |
| Cover Warranty | 1 Year |
| Electromechanical Mattress Components Warranty | 1 Year |
Joerns DermaFloat Low Air Loss Mattress System User Manual & Brochure
Frequently Asked Questions (FAQs)
What is the Joerns DermaFloat® Low Air Loss Mattress System used for?
The Joerns DermaFloat® Low Air Loss Mattress System is designed to help prevent and manage pressure injuries (pressure ulcers or bed sores) in patients who spend extended periods in bed. Its advanced low air loss technology and pressure redistribution therapy help reduce prolonged pressure, regulate heat and moisture, and support skin integrity, making it ideal for hospitals, long-term care facilities, rehabilitation centers, and home healthcare.
How does low air loss therapy help prevent pressure ulcers?
Low air loss therapy continuously circulates air through the mattress to reduce heat and moisture buildup while maintaining a healthy skin microclimate. Combined with the mattress's 20-cell pressure redistribution system, this helps minimize pressure on vulnerable areas, reduce skin maceration, improve patient comfort, and lower the risk of developing pressure injuries.
What types of patients can benefit from the DermaFloat LAL Mattress?
The DermaFloat LAL is recommended for patients who require extended bed rest or advanced pressure redistribution therapy. It is clinically indicated for the prevention and treatment of Stage 1–4 pressure injuries and is suitable for patients recovering from surgery, burns, neurological conditions, amputations, dermatological conditions, rehabilitation, arthritis, oncology treatments, and other conditions that increase the risk of skin breakdown.
What is the maximum weight capacity of the Joerns DermaFloat Mattress?
The Joerns DermaFloat Low Air Loss Mattress System safely supports patients weighing up to 500 lbs. It is available in 36-inch and 42-inch widths and features a full mattress replacement design with integrated CairRails® side bolsters for enhanced patient safety and stability.
What therapy modes does the Joerns DermaFloat Low Air Loss Mattress offer?
The DermaFloat LAL features three therapeutic operating modes to meet a variety of patient care needs: Autofirm Mode: Quickly firms the mattress for safer patient transfers and caregiving tasks. Therapy Mode: Provides continuous pressure redistribution to help prevent and treat pressure injuries. Pulsate Mode: Gently alternates pressure to enhance comfort while supporting circulation and lymphatic function during long-term bed rest.
